Business Description
PTC Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US69366J2006
Share Class Description:
PTCT: Ordinary SharesTotal Employee Number:
991Compare
Compare
Traded in other countries / regions
PTCT.USABH3.Germany Index Membership
Russell 2000Russell 3000Russell 1000 IPO Date
2013-06-20Description
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.2 | |||||
Equity-to-Asset | -0.05 | |||||
Debt-to-Equity | -4.21 | |||||
Debt-to-EBITDA | 4.01 | |||||
Interest Coverage | 0.63 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 0.89 | |||||
Beneish M-Score | -1.78 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 26.2 | |||||
3-Year Book Growth Rate | 19 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 29.76 | |||||
9-Day RSI | 35.6 | |||||
14-Day RSI | 38.37 | |||||
3-1 Month Momentum % | 12.48 | |||||
6-1 Month Momentum % | 11.1 | |||||
12-1 Month Momentum % | 60.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.39 | |||||
Quick Ratio | 3.28 | |||||
Cash Ratio | 2.89 | |||||
Days Inventory | 344.26 | |||||
Days Sales Outstanding | 75.25 | |||||
Days Payable | 180.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.7 | |||||
Shareholder Yield % | -2.4 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 92.99 | |||||
Operating Margin % | 11.57 | |||||
Net Margin % | -3.81 | |||||
EBITDA Margin % | 17.2 | |||||
FCF Margin % | -32.97 | |||||
OCF Margin % | -3.02 | |||||
ROA % | -1.34 | |||||
ROIC % | 5.54 | |||||
3-Year ROIIC % | 659.45 | |||||
ROC (Joel Greenblatt) % | 92.05 | |||||
ROCE % | 5.83 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 39.03 | |||||
PS Ratio | 6.11 | |||||
EV-to-EBIT | 36.33 | |||||
EV-to-Forward-EBIT | 76.74 | |||||
EV-to-EBITDA | 24.75 | |||||
EV-to-Forward-EBITDA | 58.09 | |||||
EV-to-Revenue | 4.26 | |||||
EV-to-Forward-Revenue | 3.36 | |||||
EV-to-FCF | -12.91 | |||||
Price-to-GF-Value | 1.85 | |||||
Price-to-Median-PS-Value | 1.11 | |||||
Earnings Yield (Greenblatt) % | 2.75 | |||||
FCF Yield % | -5.71 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PTCT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PTC Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,008.754 | ||
| EPS (TTM) ($) | -0.58 | ||
| Beta | 1.4151 | ||
| 3-Year Sharpe Ratio | 0.53 | ||
| 3-Year Sortino Ratio | 0.78 | ||
| Volatility % | 48.17 | ||
| 14-Day RSI | 38.37 | ||
| 14-Day ATR ($) | 2.572985 | ||
| 20-Day SMA ($) | 72.19775 | ||
| 12-1 Month Momentum % | 60.47 | ||
| 52-Week Range ($) | 48.275 - 90.87 | ||
| Shares Outstanding (Mil) | 83.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PTC Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PTC Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-19 16:30 | In 182 days | ||
| Annual report for 2026 | 2027-02-19 | In 181 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-19 | In 181 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 16:30 | In 75 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 74 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 16:30 | 74.49 (-0.48%) | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 74.49 (-0.48%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 09:20 | 70.87 (-0.13%) | ||
| General meeting for 2026 | 2026-06-02 09:00 | 73.80 (+0.71%) | ||
| Guidance call for 2026 | 2026-05-20 10:00 | 70.31 (-0.14%) |
Show
Entries
PTC Therapeutics Inc Frequently Asked Questions
What is PTC Therapeutics Inc(PTCT)'s stock price today?
The current price of PTCT is $69.82. The 52 week high of PTCT is $90.87 and 52 week low is $48.28.
When is next earnings date of PTC Therapeutics Inc(PTCT)?
The next earnings date of PTC Therapeutics Inc(PTCT) is 2026-11-04 Est..
Does PTC Therapeutics Inc(PTCT) pay dividends? If so, how much?
PTC Therapeutics Inc(PTCT) does not pay dividend.
Press Release
Articles on PTC Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers